BBNX

Beta Bionics, Inc. Common Stock

23.50 USD
+0.03
0.13%
At close Feb 7, 4:00 PM EST
Pre-market
25.02
+1.52
6.47%
1 day
0.13%
5 days
-2.08%
1 month
-0.55%
3 months
-0.55%
6 months
-0.55%
Year to date
-0.55%
1 year
-0.55%
5 years
-0.55%
10 years
-0.55%
 

About: Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product include the iLet Bionic Pancreas (iLet). The Company operates as single segment, focused on the development, manufacture and sale of the iLet.

Funds holding %
Analysts bullish %

Fund manager confidence

Research analyst outlook

We haven’t received any recent analyst ratings for BBNX.

Financial journalist opinion

Based on 6 articles about BBNX published over the past 30 days

Positive
24/7 Wall Street
23 hours ago
Insider Buying Surges in February, Especially in These 6 Stocks
In January, the number of notable insider purchases was somewhat muted.
Insider Buying Surges in February, Especially in These 6 Stocks
Positive
Seeking Alpha
1 week ago
Beta Bionics: A Sugar Rush For This IPO
Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company's iLet product offers a new, simplified treatment for Type 1 diabetes, with plans to expand to Type 2, doubling the market potential. Despite impressive revenue growth, Beta Bionics faces substantial operating losses, but it has a solid cash position to fund these losses for years.
Beta Bionics: A Sugar Rush For This IPO
Positive
Seeking Alpha
1 week ago
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK Technology, and TV Channels Network. Two IPOs are currently scheduled for the week ahead, and a few more sizable names are eligible to launch.
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Neutral
GlobeNewsWire
1 week ago
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters' option to purchase 1,800,000 additional shares, consisting of 475,000 additional shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus, at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Beta Bionics, were approximately $212.1 million. Beta Bionics did not receive any proceeds from any sale of shares by the selling stockholders. The shares began trading on the Nasdaq Global Market on January 30, 2025 under the ticker symbol “BBNX.”
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Neutral
GlobeNewsWire
1 week ago
Beta Bionics Announces Pricing of Upsized $204 Million Initial Public Offering
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Beta Bionics, are expected to be $204.0 million. In addition, the underwriters have a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the public offering price, less underwriting discounts and commissions, consisting of 475,000 shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus. Beta Bionics will not receive any proceeds from any sale of shares by the selling stockholders.
Beta Bionics Announces Pricing of Upsized $204 Million Initial Public Offering
Positive
Seeking Alpha
4 weeks ago
U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline
Three very small Asian issuers and one blank check company listed in the US this past week, though the biggest headlines came from a sizable launch and notable new filings. Energy equipment and services provider Flowco launched the year's first major IPO, planning to raise $392 million and list in the week ahead. Two IPOs are currently scheduled in the week ahead, although some other small issuers may join the calendar throughout the week.
U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline
Negative
Seeking Alpha
1 month ago
Beta Bionics Aims For IPO To Cover Heavy Losses
Beta Bionics is rapidly growing revenue but faces significant operating losses with no clear path to profitability in the near term. The firm is commercializing the FDA-cleared iLet Bionic Pancreas and developing additional insulin delivery technologies, including a patch pump. The company plans to raise $100 million in an IPO to fund product development, regulatory submissions, and expansion of sales and manufacturing infrastructure.
Beta Bionics Aims For IPO To Cover Heavy Losses
Charts implemented using Lightweight Charts™